Advertisement

Organisation › Details
Oblique Therapeutics AB (publ)
AAX Biotech AB is a biotech company specializing in next-generation antibody therapeutics. The company offers two unique and proprietary technologies, Seqitope™ and Opti-mAb™, that enable high-throughput and high-resolution epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells. Both technologies aim to produce better and more effective antibody-based medicines. These innovations position AAX Biotech as a key player in the rapidly growing antibody therapeutics market. AAX Biotech is founded by experts from Karolinska Institutet in Stockholm, Sweden. *
![]() |
Start | 2023-11-28 existent |
![]() |
Industry | therapeutic antibody |
Industry 2 | AbiProt® methodology | |
![]() |
Person | Nordstedt, Christer (Oblique Therapeutics 202311 CEO before Vivesto) |
Person 2 | Jonasson, Mats (Oblique Therapeutics 202312 CFO) | |
![]() |
Region | Göteborg (Gothenburg) |
Country | Sweden | |
Street | 20 Arvid Wallgrens Backe | |
City | 41346 Göteborg | |
Address record changed: 2023-12-03 | ||
Basic data | Employees | n. a. |
�About Section� taken from web site of organisation on 01.12. | ||
Record changed: 2024-02-12 |
Advertisement

More documents for Oblique Therapeutics AB (publ)
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top